Bone & Joint Open · 2023 · 16 citations · 21 references
PharmacyOrthopedic SurgerySurgeryCost-effectiveness AnalysisCost-utility AnalysisOrthopedicsCost-effectiveness ComparisonEconomic EvaluationIncremental Cost-effectiveness AnalysisIncremental Cost-utility RatiosKnee ArthroplastyRobotic-assisted ArthroplastyCost-effectiveness Of Robotic SurgeryDifferential CostsEuroqol Five DimensionsIncremental Cost-benefit AnalysisIncremental Cost-utility AnalysisQaly GainsRobotic-assisted Knee ArthroplastySurgical Cost-effectiveness Analysis
Aims: To perform an incremental cost-utility analysis and assess the impact of differential costs and case volume on the cost-effectiveness of robotic arm-assisted unicompartmental knee arthroplasty (rUKA) compared to manual (mUKA). Methods: This was a five-year follow-up study of patients who were randomized to rUKA (n = 64) or mUKA (n = 65). Patients completed the EuroQol five-dimension questionnaire (EQ-5D) preoperatively, and at three months and one, two, and five years postoperatively, which was used to calculate quality-adjusted life years (QALYs) gained. Costs for the primary and additional surgery and healthcare costs were calculated. Results: rUKA was associated with a relative 0.012 QALY gain at five years, which was associated with an incremental cost per QALY of £13,078 for a unit undertaking 400 cases per year. A cost per QALY of less than £20,000 was achieved when ≥ 300 cases were performed per year. However, on removal of the cost for a revision for presumed infection (mUKA group, n = 1) the cost per QALY was greater than £38,000, which was in part due to the increased intraoperative consumable costs associated with rUKA (£626 per patient). When the absolute cost difference (operative and revision costs) was less than £240, a cost per QALY of less than £20,000 was achieved. On removing the cost of the revision for infection, rUKA was cost-neutral when more than 900 cases per year were undertaken and when the consumable costs were zero. Conclusion: rUKA was a cost-effective intervention with an incremental cost per QALY of £13,078 at five years, however when removing the revision for presumed infection, which was arguably a random event, this was no longer the case. The absolute cost difference had to be less than £240 to be cost-effective, which could be achieved by reducing the perioperative costs of rUKA or if there were increased revision costs associated with mUKA with longer follow-up.
21
EuroQol - a new facility for the measurement of health-related quality of life
Health Policy · 1990 · 15.8K citations
Modeling Valuations for EuroQol Health States
Paul Dolan · Medical Care · 1997 · 4.6K citations
Predicting the cost-effectiveness of total hip and knee replacement
P Jenkins, Nick D. Clement, David Hamilton et al. · The Bone & Joint Journal · 2013 · 323 citations
David Beard, Loretta Davies, Jonathan Cook et al. · The Lancet · 2019 · 302 citations · Full text